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Y.S. Alimi1Departments of 1Vascular Surgery, and 2Medical Statistics, Hoˆpital Nord, Marseille, FrancePurpose. To assess the results of covered stents in the treatment of superficial femoral artery (SFA) occlusive disease.
Method. From July 2000 till June 2003, 32 patients (34 limbs) were scheduled for procedures including Hemobahnw
deployment in the SFA. Indication for treatment was claudication (group I, NZ15 patients and 16 limbs, 31.2% occlusions)
or critical and acute ischemia (group II, NZ17 patients and 18 limbs, 61.1% occlusions). TASC D SFA lesions were
excluded. No limb artery was patent pre-operatively in 19% and 89% of limbs in groups I and II, respectively (pZ0.00001).
Results. Outflow procedures were performed simultaneously in one limb in group I and 12 in group II (pZ0.0003). The
technical, hemodynamic and clinical success rates were 100, 100 and 94.1%, respectively. Mean follow-up was 18.1 months.
Primary patency rates at 12 months were 81.3G10.6% in group I and 88.6G9.0% in group II (pZ0.547). At 12 months,
the secondary patency and limb salvage rates were, respectively, 87.5G8.9 and 100% in group I and 87.5G8.93 and
94.45G6.71% in group II.
Conclusion. Treatment of SFA occlusive lesions (excluding TASC D lesions) with the Hemobahnw covered stent yielded
good results for both claudicants with good outflow and patients with critical or acute ischemia with bad outflow, if
concomitant outflow-improving procedures were performed.Keywords: Superficial femoral artery; Occlusive disease; Stent-graft; Hemobahn; Critical limb ischemia; Poor outflow.The gold standard technique for the treatment of
infrainguinal arterial stenoses or occlusions remains
bypass. Femoropopliteal bypass has a patency rate at 5
years of, respectively, 80% for claudicants and 66% for
critical limb ischemia (CLI) when using the saphenous
vein, but only 75 and 47% with above-knee PTFE
grafts.1
Endovascular techniques have modified the treat-
ment of infrainguinal lesions and at present are used
widely, with interesting but variable results. Patency
rates for the TASC meta-analysis ranged between 61
and 67% at 1 year and 51 and 58% at 3 years,
depending on patient clinical status and the use of
stents.2 The main predictive factors were lesion length,
lesion eccentricity, major calcification, post-angio-
plasty residual stenosis, run-off and clinical presen-
tation (CLI).2
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0300+ 07 $35.00/0 q 2005 Published by Elsevier Ltd.transluminally placed endovascular grafts (TPEGs) in
the femoropopliteal segment.3 Since then, different
devices (home-made or more recently commercial)
have been used.
The TASC2 group did not reach any conclusions
concerning the best way to treat SFA type B and C
lesions. The goal of this study is to compare the results
of lower limb revascularization using TPEGs (Hemo-
bahnw, W. L. Gore and Associates, Flagstaff, AZ, USA)
for superficial femoral artery (SFA) occlusive disease
in patients with claudication and acute (ALI) or critical
limb ischemia (CLI) with TASC B or C lesions.MethodsStudy design
All patients scheduled (intention to treat) for TPEG
implantation during the treatment of SFA occlusive
disease, between July 2000 and June 2003 were
included. Inclusion criteria were patients withEur J Vasc Endovasc Surg 30, 300–306 (2005)
doi:10.1016/j.ejvs.2005.04.027, available online at http://www.sciencedirect.com on
Hemobahnw for Critical and Acute Ischemia 301claudication, CLI or ALI related to SFA stenosis or
occlusion with or without inflow and outflow lesions.
Exclusion criteria were SFA of less than 5 mm in
diameter, ostial or chronic complete occlusion of the
SFA (TASC type D), extension of the lesion precluding
later femoropopliteal above-knee bypass, absence of
an above-knee patent popliteal artery (TASC type D),
embolic acute limb ischemia (ALI) and ALI category
IIb and III.4 All definitions are in accordance with the
standards suggested by Rutherford.4 All patients had
a pre-operative duplex scan and digitalized angiogra-
phy (20 patients) or MRA (12 patients).Technique
All procedures were performed in the operating room.
After catheterization with a 0.035 0 Terumo guidewire,
insertion of the sheath and performance of an
angiogram, heparin and an antiplatelet drug (500 mg
of aspirin) were administrated intravenously. In cases
of occlusion, recanalization was performed translum-
inally (Fig. 1). The lesion was predilated then the
guidewire was exchanged for a 0.025 Terumo and the
Hemobahnw TPEG(s) was/were deployed. The
Hemobahnw is composed of a self-expanding nitinol
stent covering an ultrathin expanded PTFE graft. After
balloon dilatation of the stent-graft, a completion
angiogram, which also evaluated outflow, was
performed.
Post-operatively, from the 6th-hour, nadroparin was
given subcutaneously, 2850 or 3800 UI every 12 h
depending on the patient’s weight (less or more than
70 kg) until discharge. In addition, two antiplatelet
drugs (aspirin and clopidogrel) were given for 1
month, and only one of the two thereafter. In cases of
associated pathology or vascular reconstruction
requiring long term anticoagulation, fluindion was
associated with clopidogrel.
Follow-upwas performed at 1, 6 and 12months and
then annually. Clinical examination, duplex ultra-
sound color flow scan and ABI measurement were
performed at each visit.Statistical analysis
The actuarial life-table method was used on an
intention-to-treat basis. A two-tailed Fisher exact
probability test was then performed to distinguish in
which groups there were significant differences. The
Kaplan–Meier method estimates were calculated for
overall patency and limb salvage rates and were then
compared with the log-rank test results. Patency rates
referred to the patency of the SFA procedure.ResultsPatients and lesions
From July 2000 to June 2003, 32 patients (34 limbs), 30
men and 2 women, age ranging from 52.5 to 88.7 years
(mean age: 70.1 years) were treated: demographics are
presented in Table 1. One patient, with previous
popliteal above-knee to below-knee venous bypass
for popliteal aneurysm, presented with thrombosis of
both a severely diseased SFA and the bypass second-
ary to polycythaemia. The mean pre-operative creati-
nine level was 1.17 mg/dl (range 0.64–2.1), excluding
the three patients on hemodialysis. Three limbs (8.8%)
were classified as Rutherford category 2, 13 (38.2%)
category 3, 3 (8.8%) category 4 and 11 (32.4%) category
5. Four patients (11.8%) had acute ischemia, one
category I and three category IIa. The claudicants’
mean walking distance was 131 m (range 30–260 m)
and their mean pre-operative ABPI (ankle–brachial
pressure index) was 0.65 (range 0.40–0.78). Eighteen
SFAwere stenosed and 16 were occluded. Mean lesion
length was 108 mm (range 30–220 mm). Inflow lesions
needing treatment were found in 14 patients (7 in each
group): 8 common femoral artery (CFA), 2 common
iliac artery and 1 external iliac artery stenoses and 3
anastomotic false aneurysms on the CFA. Run-off was
considered normal in nine limbs. Popliteal artery
stenosis was found in 10 patients (nine with CLI).
Three or two infrapopliteal arteries were patent in 15
limbs (13 claudicants) and 1 or 0 in 19 (16 critical or
acute ischemia). These lesions were classified TASC2
type B in 13 cases and type C in 21. Outflow was
statistically worse in patients with critical and acute
ischemia (pZ0.00001) and but the higher number of
occlusions failed to achieve statistical significance (pZ
0.08).Procedures
Three procedures were performed under local
anesthesia and 30 under general anesthesia (one
simultaneous bilateral). Percutaneous access to the
CFA was obtained in 13 cases (38.2%). The CFA was
surgically approached in 20 cases (58.8%) due to
inflow (CFA or iliac) lesions (14 limbs), unsuccessful
percutaneous access (three limbs) or the need for other
associated surgical procedures (three cases). In one
case, the sheath was inserted into the below-knee
popliteal artery (associated popliteal pedal bypass).
Sheath size was 8 Fr in 27 limbs and 9 Fr in 7.
Technical success was achieved in 100% of patients
with recanalization achieved in all occluded SFAs; inEur J Vasc Endovasc Surg Vol 30, September 2005
Fig. 1. Eighty-one year old man with right limb critical ischemia (A) pre-operative angiography: 10 cm long occlusion of the
SFA and occlusion of the anterior and posterior tibial arteries (B) and (C) per-operative views of the Hemobahn after
deployment before and after contrast injection (D) MRA 36 months after percutaneous recanalization and 15 cm long 6 mm
Hemobahn placement: patent SFA without restenosis.
Table 1. Risk factors and history
Claudi-
cants
Critical and
acute ischemia
p
N patients 15 17
Smoking 14 (93.3%) 15 (88%) 0.55
Arterial hypertension 15 (100%) 10 (58.8%) !0.01
Hyperlipidemia 6 (40%) 7 (41.2%) 0.95
Diabetes mellitus 7 (46.7%) 10 (58.8%) 0.49
Ischemic heart
disease
7 (46.7%) 7 (41.2%) 0.75
Renal insuffiency 0 4 (23.5%) (3 HD) 0.07
Obesity 10 (66.7%) 7 (41.2%) 0.15
Cancer 2 (13.3%) 1 (5.8%) 0.45
COPD 4 (26.6%) 4 (23.5%) 0.84
Previous ipsilateral
revascularisation
2 (13.3%) 5 (29.4%) 0.25
Previous controlateral
revascularisation
6 (40%) 7 (41.2%) 0.95
Controlateral limb
amputation
0 1 (5.9%) 0.53
Previous carotid
surgery
6 (40%) 4 (23.5%) 0.31
COPD, chronic obstructive pulmonary disease; HD, hemodialysis.
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Eur J Vasc Endovasc Surg Vol 30, September 2005one case, we noted dye extravasation at the level of the
recanalization after balloon angioplasty (BA). In two
cases, above-knee embolic occlusion was found after
recanalization; it was treated with aspiration of the
thrombus. Forty Hemobahn were deployed (2 in 6
limbs); 7 mm stent-grafts were used in 7 limbs and
6 mm in all the others. The mean length of the TPEG
treated artery was 141 mm (range 50–250 mm). Con-
comitant inflow and outflow procedures also were
performed as scheduled: two CIA BA and stenting,
one BA of external iliac artery, three resections of
femoral false aneurysms, nine CFA surgical angio-
plasty, eight BA of popliteal artery (two stents), one
popliteal above- to below-knee venous bypass plus
popliteal below-knee to anterior tibial artery bypass,
one below-knee popliteal pedal venous bypass, one
anterior tibial artery and one peroneal artery BA
(Table 2). The number of procedures performed on
the outflow was higher in patients with acute and
critical ischemia (pZ0.0003). Completion angiography
Table 2. Lesion characteristics
Claudicants Critical and acute ischemia p Total
N limbs 16 18 34
Mean length (mm) 98 117 108
Occlusion 5 (31.2%) 11 (61.1%) 0.08 16 (47.1%)
Inflow lesions 7 (43.7%) 7 (38.9%) 0.77 14 (41.1%)
Outflow
Thrombosed popliteal bypass 0 1 (5.5%) 1 (2.9%)
Popliteal stenosis 1 (6.25%) 9 (50%) 10 (29.4%)
2–3 limb arteries 13 (81.3%) 2 (11.1%) 15 (44.1%)
0–1 limb artery 3 (18.7%) 16 (88.9%) 0.00001 19 (55.9%)
TASC lesion type
B 8 (50%) 5 (37.8%) 0.18 13 (38.2%)
C 8 (50%) 13 (72.2%) 21 (61.8%)
Outflow procedure 1 (6.3%) 12 (66.7%) 0.0003 13 (38.2%)
Popliteal artery 1 (6.3%) 9 (50%) 10 (29.4%)
Limb artery PTA 0 2 (11.1%) 2 (5.9%)
Infra-popliteal bypass 0 2 (11.1%) 2 (5.9%)
Hemobahnw for Critical and Acute Ischemia 303showed no significant residual stenosis along the
TPEG and no distal emboli.
Post-operatively, the popliteal pulse was felt in all
limbs. Distal pulses were found on 23 limbs. Hemo-
dynamic improvement was obtained post-operatively
in 100% of the limbs. There were no cases of post-
operative renal insuffiency.Follow-up
Mean stay in hospital was 6.03 days (1–25) and mean
follow-up was 18.1 months (2.1–40), summarized in
Table 3.Follow-up in claudicants (NZ15 patients, 16 limbs)
No deaths occurred in this group and follow-up wasTable 3. Follow-up (patency and limb salvage rates were calculated a
Claudicants
Length of stay (days) 4.25 (1–9)
Follow up (months) 23.5
Death 0
Thrombosis
Post-operative 2
Late (O30 days) 1
One month
Primary patency 87.5G5.9%
Secondary patency 93.8G5.9%
Limb salvage 100%
Survival 100%
One year
Primary patency 81.2G10.6%
Secondary patency 87.5G8.9%
Limb salvage 100%
Survival 100%
Two year
Primary patency 81.3G15.7%
Secondary patency 87.5G12.6%
Limb salvage 100%
Survival 100%uneventful in 12 patients (13 limbs). Post-operatively,
the popliteal pulse was palpable in all patients and
distal pulse(s) in 14. The mean hospital length of stay
was 4.35 days (1–9) and clinical success at day 30 was
achieved in 15 limbs (93.7%).
One patient had Hemobahn thrombosis at 25 days:
after thrombectomy angiography did not reveal any
lesions. Rethrombosis occurred the following day and
an above-knee ePTFE femoropopliteal bypass was
performed. It occluded 4 months later and was
thrombectomized. The rethrombosis was treated
with a below-knee femoro-popliteal venous bypass.
The stent-graft in another patient occluded at day 27,
following endoscopic resection of a prostatic adenoma
(performed after 7 days’ interruption of the antiplate-
let treatment). Surgical thrombectomy with a Fogarty
catheter was successful.ccording to Kaplan–Meyer method estimates)
Critical and acute ischemia Total
7.61 (1–25) 6.03 (1–25)
13.4 18.1
5 (29.4%) 5 (15.6%)
0 2
2 3
100% 91.2G4.8%
100% 94.1G4%
94.5G5.2% 97.1G2.9%
100% 100%
88.5G9% 85G7.4%
88.5G9% 87.9G6.7%
94.5G6.7% 97G3.5%
69.5G12.1% 83.9G7.3%
88.5G17.3% 85G13.4%
88.5G17.3% 87.9G13.7%
94.5G12.8% 97G5.5%
69.5G22.2% 83.9G11.9%
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O. Hartung et al.304One Hemobahn occluded 4.4 months after deploy-
ment: this event was asymptomatic and 20 months
later, the patient presented with Rutherford category 1
chronic limb ischemia. All other claudicants were
asymptomatic. All limbs with a patent TPEG (NZ13)
had a popliteal pulse and 11 had distal pulse(s). Their
mean ABPI at the end of the follow-up was 0.92 (0.74–
1.11).
Primary and secondary patency rates were, respec-
tively, 87.5%G8.0 and 93.8%G5.9 at 1 month, 81.3%G
10.6 and 87.5%G8.9 at 1 year, 81.3%G15.7 and 87.5G
12.6 at 2 years. Limb salvage and survival rates were
100% at 2 years.Follow-up in CLI/ALI (NZ17 patients, 18 limbs)
Five deaths occurred during follow-up. The Hemo-
bahn was patent in all the patients who died except
one, in whom there was thigh amputation. The causes
of death were cardiac failure in two patients, myocar-
dial infarction in one, hepatic metastasis in one, and
unknown in one.
Mean hospital length of stay was 7.6 days (1–25).
The post-operative course (until day 30) was normal
and free of complications in 12 patients (13 limbs). Five
complications occurred: one case of angina pectoris
medically treated, one groin hematoma (no reinter-
vention), one retroperitoneal hematoma which
required surgical treatment (patient discharged at
day 5 and died 2 months later with a patent TPEG),
one superficial sepsis of the groin after surgical
approach treated surgically (discharged at day 25)
and one case of aggravation of distal ischemia (despite
a patent Hemobahn) at day 7 requiring first below
knee amputation then thigh amputation 2months later
despite a patent Hemobahn (patient with cardiac
failure on hemodialysis).
Clinical success was achieved in 17 limbs (94.4%)
and all the ulcers healed except one in a patient
requiring amputation. One patient who had a SFA
Hemobahn implantation and popliteal and peroneal
PTAs (same limb) returned 6 months later with an
occlusion of the proximal peroneal artery: a popliteal
peroneal vein bypass was performed (Fig. 2). Another
patient with an SFA Hemobahn and popliteal BA
thrombosed at 3.8 months and was treated with a
venous femoro-peroneal bypass. All other patients
were improved and presented at most category 2
chronic limb ischemia.
The primary and secondary patency rates were
100% at 1 month, 94. 5G5.4% at 3 months, 88.5G9.0%
at 1 year and 88.5G17.3 at 2 years. The limb salvage
rate was 94.5G5.2% at 1 month, 94.5G6.7% at 1 year
and 94.5G12.9% at 2 years. The survival rate was 100%Eur J Vasc Endovasc Surg Vol 30, September 2005at 1 month, 69.5G12.1% at 1 year and 69.5G22.2% at 2
years.
Log-rank tests did not reveal any statistical differ-
ence between the two groups in terms of primary (pZ
0.547) or secondary (pZ0.94) patency.Discussion
TPEGs were initially developed to treat aneurysmal5
and traumatic lesions,6 with interesting results. They
were subsequently used to treat occlusive disease of
the iliac and superficial femoral (SFA) arteries. The
goal of these stent-grafts is to improve the results of
transluminal angioplasty by preventing in-stent devel-
opment of intimal hyperplasia, thus both reducing
restenosis and increasing patency.
Stent grafting with the first TPEGs used for the
treatment of SFA occlusive disease gave somewhat
disappointing results. Rodriguez-Lopez reported 46%
primary and 68% secondary patency rates at 2 years
with a home-made endoluminal graft.7 Ahmadi8 with
a Dacron-covered TPEG (Wallgraft) reported primary
and secondary patency rates of, respectively, 23 and
60% at 1 year despite post-operative treatment with
aspirin and oral anticoagulation therapy. The results
were no better with the Cragg Endopro System I:
Maynar9 had an overall primary patency rate of 45%
with mean follow-up of 17.2 months. These implan-
tations were associated with a considerable number of
complications (thrombosis, hematoma, perforation,
migration etc).
The Hemobahnw was developed by W. L. Gore and
Associates. It consists in a self-expanding nitinol stent
internally covered with ultrathin PTFE premounted
folded on a delivery catheter. Virmani showed that use
in canine iliac and femoral arteries did not induce
significant intimal hyperplasia.10
Studies of the Hemobahnw used in the treatment of
SFA occlusive disease have been conducted in 10 series
including this one11–19: data summarized in Table 4.
The clinical presentation were very different, ranging
from 0 to 74% of critical limb ischemia. Likewise,
although the SFA lesions were not similar (47–100% of
limbs had SFA occlusion and mean lesion length
ranged from 108 to 220 mm) most of them were
classified as TASC grade B or C. Despite this, the
primary and secondary patency rates, respectively, for
Hemobahn ranged between 58 and 93% and between
73 and 93% at 1 year. In the main, these results are
better than those for PTA or stenting of TASC grade A,
B or C lesions (primary patency at 1 year 61 and 67%,
respectively). These data are consistent with the only
publication reporting a prospective randomized
Fig. 2. Eighty-two year old man with acute right limb ischemia level I (A) pre-operative angiography: 8 cm long mid SFA
occlusion with stenosis of the tibioperoneal trunk, complete occlusion of the anterior and posterior tibial arteries and pre-
occlusive stenosis of the origin of the peroneal artery (B) and (C) pre-operative angiography: result of the SFA recanalization
and stenting with a 6 mm 10 cm long Hemobahn (B) and of the peroneal angioplasty (C, D) angiography 6 months after
surgery: thrombosis of the middle popliteal artery and thrombosis of the tibioperoneal trunk. The Hemobahn implanted in
the SFA stayed patent (E) and (F) proximal (E) and distal (F) anastomoses of an above knee popliteal peroneal bypass
performed just distal to the Hemobahn.
Hemobahnw for Critical and Acute Ischemia 305comparison of PTA versus Hemobahnw:16 primary
patency at 2 years 25 versus 87%.
Fischer18 showed that the results were better on
ideal indications (segments with a length of R1 cm
proximal and distal without any obstruction, no
lesions in the popliteal artery, at least one open lower
leg vessel and no severe calcifications) with patency
rates of 89 versus 74% at 2 years. Bray15 noted that
primary and secondary patency rates might be slightly
higher in the poor run-off group (pZ0.157), while
clinical status did not have an influence on the result.
This study is the only one that compares the results
in relation to pre-operative clinical status. Patients
with acute or critical limb ischemia had worse outflow
(87.9% with less than two patent limb arteries versus
18.7%, p!0.00001), more previous ipsilateral revascu-
larization (29.4 versus 13.3%), more occlusions (61.1versus 31.2%) and longer lesions (117 versus 98 mm).
Despite this, patency and limb salvage rates were not
different. This could be explained by the large number
of cases of outflow revascularization (66.7 versus 6.3%,
pZ0.0003) performed in this group during the same
procedure. Our results need to be confirmed by larger
studies with a longer follow-up. Moreover, patients
with TASC D lesions were excluded, so no conclusions
can be drawn for such lesions which represent the
most common situation in CLI.
The main concern with this device is its cost, 2500V
for a 10 cm long Hemobahnw in our institution while
bare stents cost around 700V. The indications for the
use of TPEGs are different from bare stents, more
comparable to above-knee femoropopliteal bypass.
The shorter length of stay made possible by endovas-
cular procedures, particularly if the approach isEur J Vasc Endovasc Surg Vol 30, September 2005
Table 4. Comparison with the literature11–19
N limbs CLI (%) Occlusion (%) Length (mm) Success (%) Follow-up
(months)
PP/SP rates
Lammer 80 11 62 131* 100 O12M 1Y: 78.7%/93.4%
Bauermeister 35 74 100 220 100 7M 1Y: 73.2%/82.6%
Deutschmann 18 0 94 6M: 49%/61%
Railo 15 60 66.7 100 17.3 1Y: 93%/NS
Bray 59 17 100 178 95 1Y: 58%/73%
Jahnke 52 82.7 109* 100 23.8M 1Y: 78.4%/88.3%
Saxon 15 100 O24M 2Y: 87%
Turicchia 16 25 50 93.8 12 1Y: 80%/84%
Fischer 55 11 85 116 100 33M 2Y: 61%/76%
Hartung 34 53 47 108 100 18.1M 1Y: 85%/87.9%
Claudicants 16 0 31.2 98 100 23.5M 1Y: 81.2%/87.5%
ALI/CLI 18 100 61.1 117 100 13.4M 1Y: 88.5%/88.5%
CLI, critical limb ischemia; NS, not specified.
* Mean length of covered SFA.
O. Hartung et al.306percutaneous, could compensate for the higher cost of
the Hemobahnw.Conclusion
The Hemobahnw is a good way of treating long SFA
stenosis and/or occlusions excluding TASC D lesions,
with low peri-procedural complication rates. Patients
with acute/critical limb ischemia presenting with
popliteal and infrapopliteal associated lesions can
also benefit from this endovascular treatment with
results as good as those for claudicants with good
outflow, particularly if concomitant outflow improv-
ing procedures are performed. Our results will have to
be confirmed by larger studies and to be compared to
bare stents and bypasses (including a cost evaluation
of each technique).References
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